No data to show
XNAS
FBLG
Market cap33mUSD
Jun 12, Last price
0.87USD
1D
0.29%
1Q
-14.46%
IPO
-95.01%
Name
Fibrobiologics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-11m
L-32.30%
CFO
-12m
L+85.92%
Profile
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | |
| Income | ||||
Revenues | ||||
Cost of revenue | 13,737 | 9,326 | 4,467 | |
Unusual Expense (Income) | ||||
NOPBT | (13,737) | (9,326) | (4,467) | |
NOPBT Margin | ||||
Operating Taxes | ||||
Tax Rate | ||||
NOPAT | (13,737) | (9,326) | (4,467) | |
Net income | (11,161) -32.30% | (16,485) 221.91% | (5,121) 223.70% | |
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 7,507 | 16,138 | 2,150 | |
BB yield | -11.42% | |||
| Debt | ||||
Debt current | 9,569 | 362 | 5,777 | |
Long-term debt | 2,369 | 3,132 | 3,494 | |
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | (2,047) | (5,669) | 7,005 | |
| Cash flow | ||||
Cash from operating activities | (11,901) | (6,401) | (4,066) | |
CAPEX | (184) | (495) | ||
Cash from investing activities | (184) | (495) | ||
Cash from financing activities | 16,907 | 13,793 | 5,925 | |
FCF | (13,348) | (9,733) | (6,666) | |
| Balance | ||||
Cash | 13,985 | 9,163 | 2,266 | |
Long term investments | ||||
Excess cash | 13,985 | 9,163 | 2,266 | |
Stockholders' equity | (35,518) | (24,356) | (6,410) | |
Invested Capital | 48,806 | 27,356 | 9,938 | |
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 32,875 | 28,231 | 32,492 | |
Price | 2.00 | |||
Market cap | 65,750 | |||
EV | 63,703 | |||
EBITDA | (13,164) | (8,889) | (4,373) | |
EV/EBITDA | ||||
Interest | 20 | 147 | 654 | |
Interest/NOPBT | ||||